Cytel

Cytel is a pioneering data-science CRO, committed to driving advancements in human health through robust analytics and innovative clinical trial software. Established in 1987, the company has been at the forefront of adaptive trial design, leveraging extensive data insights to inform strategy throughout every phase of drug development and commercialization. With a mission to accelerate drug development, enhance success rates, and deliver better patient outcomes, Cytel offers a comprehensive suite of services, including innovative trial design, end-to-end biometrics, and real-world evidence. Headquartered in Cambridge, Massachusetts, Cytel boasts a global presence with over 2,000 employees across North America, Europe, and Asia. Their specialized, multidisciplinary team ensures optimal strategies for preclinical research, trial execution, market access, and reimbursement. The company secured its latest investment in a Venture Round on 01 January 2021, with Nordic Capital as the investor. Cytel's commitment to harnessing the power of data to advance human health underscores its position as a leader in the life sciences industry. For further information, visit www.cytel.com.